Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03159117 · ClinicalTrials.gov registry record · Phase 1
Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT03159117: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03159117 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03159117, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this research study is to learn about the safety and effectiveness of the study drug, PF-06688992. Before this study, PF-06688992 has never been given to people. PF-06688992 is a targeted therapy for people with cancer. The investigators linked a chemotherapy drug to an antibody (protein found in the blood). The antibody will connect to GD3 which is found on most melanomas but on very few other cells in the body. The investigators hope that in this way, it will deliver this chemotherapy directly to the melanoma and not to normal tissues.
Interventions
- DRUG PF-06688992
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2017-05-16 |
| Est. Completion | 2020-01-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03159117
The ClinicalTrials.gov registry entry for NCT03159117 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-06688992 is the first listed.
NCT03159117 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03159117 about?
NCT03159117 is a clinical study titled "Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma". The purpose of this research study is to learn about the safety and effectiveness of the study drug, PF-06688992. Before this study, PF-06688992 has never been given to people. PF-06688992 is a targeted therapy for people with cancer. The investigators linked a chemotherapy drug to an antibody (pro...
What is the current status of trial NCT03159117?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2017-05-16. Estimated completion is 2020-01-10.
What interventions are being tested in trial NCT03159117?
The interventions under investigation include: PF-06688992 (DRUG).
Who is sponsoring clinical trial NCT03159117?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.